Zoledronic Acid, IC-0182541
Product Introduction
Zoledronic acid is a third-generation nitrogen-containing bisphosphonate that functions as a potent inhibitor of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. By inhibiting FPPS, zoledronic acid blocks the post-translational prenylation of small GTPase proteins essential for osteoclast function and survival, leading to osteoclast apoptosis and inhibition of bone resorption. Zoledronic acid is clinically used for the treatment of osteoporosis, Paget''''s disease, hypercalcemia of malignancy, and prevention of skeletal-related events in patients with bone metastases. Beyond its anti-resorptive activity, zoledronic acid exhibits anti-tumor effects by inducing apoptosis and inhibiting proliferation, angiogenesis, and invasion of cancer cells. It also stimulates ¦Ã¦Ä T cell-mediated anti-tumor immune responses. Zoledronic acid is widely used in bone biology, cancer research, and immunology studies.
Product Features
1. Potent FPPS Inhibitor: Blocks the mevalonate pathway by inhibiting farnesyl pyrophosphate synthase.
2. Anti-Resorptive Activity: Induces osteoclast apoptosis and inhibits bone resorption.
3. Anti-Tumor Effects: Inhibits cancer cell proliferation, invasion, and angiogenesis; induces apoptosis.
4. Immunomodulatory Activity: Activates ¦Ã¦Ä T cells, contributing to anti-tumor immune responses.
5. High Purity: Supplied at 98% purity for reproducible pharmacological studies.
Specifications
Size: 10 mg / 100 mg / 1 g
CAS Number: 118072-93-8
Purity: 98%
Molecular Weight: 272.09
Molecular Formula: C5H10N2O7P2
Solubility: Water: ¡Ý10 mg/mL (as disodium salt); limited solubility in organic solvents
Storage and Stability
Storage Conditions: Store at room temperature, sealed in dry conditions. Protect from moisture.
Shelf Life: The product is stable for 36 months from the date of manufacture when stored as directed.
Protocol (For Reference Only)
Important: Zoledronic acid is hygroscopic. Store sealed in dry conditions.
1. Stock Solution Preparation: Dissolve zoledronic acid in sterile water or PBS to prepare a concentrated stock solution. For in vitro studies, typical concentrations range from 1-100 µM.
2. Osteoclast Inhibition: Treat osteoclast cultures or pre-osteoclast cells with zoledronic acid at 1-100 µM. Assess osteoclast apoptosis, resorption pit formation, and FPPS activity.
3. Cancer Cell Studies: Treat cancer cells with zoledronic acid at 10-100 µM for 24-72 hours. Assess cell viability, apoptosis, and invasion by standard assays.
4. ¦Ã¦Ä T Cell Activation: For immunology studies, treat peripheral blood mononuclear cells with zoledronic acid at 1-10 µM to activate ¦Ã¦Ä T cells. Assess ¦Ã¦Ä T cell expansion and cytokine production.
5. In Vivo Studies: Zoledronic acid is typically administered by subcutaneous or intravenous injection in rodent models at doses of 0.05-0.5 mg/kg. For bone metastasis models, dosing schedules should be optimized based on literature references.
Precautions
1. Store sealed in dry conditions to prevent moisture absorption.
2. Use appropriate vehicle controls in all experiments.
3. Zoledronic acid exhibits dose-dependent effects on bone turnover; interpret long-term treatment results with consideration of bone remodeling effects.
4. For research use only. Not for use in diagnostic or therapeutic procedures.
FAQ (Simplified)
Q1: What is the mechanism of action of zoledronic acid?
A1: Zoledronic acid inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, blocking protein prenylation essential for osteoclast function, leading to osteoclast apoptosis and inhibition of bone resorption.
Q2: What are the recommended concentrations for in vitro studies?
A2: For osteoclast inhibition studies, 1-100 µM is commonly used. For cancer cell studies, 10-100 µM. Optimize for each cell type and endpoint.
Q3: How should I store zoledronic acid?
A3: Store at room temperature, sealed in dry conditions. The product is stable for 36 months.
Q4: Can zoledronic acid be used in vivo?
A4: Yes. In rodent models, subcutaneous or intravenous administration at 0.05-0.5 mg/kg is commonly used. Consult literature for specific protocols.
Disclaimer
1. For Research Use Only. Not for use in diagnostic or therapeutic procedures.
2. Due to the variable nature of biological research, optimization of conditions is recommended for specific experimental systems.
3. This warranty is limited to the replacement of the product. The manufacturer assumes no liability for incidental or consequential damages.
4. Wear appropriate protective clothing and gloves when handling this product.
Ordering Information
Catalog Number: IC-0182541
Product Name: Zoledronic Acid
Size: 10 mg / 100 mg / 1 g
Suggested Retail Price:
10 mg: CNY ¥634.00 / USD $63.40 / EUR €76.08 / JPY ¥11412.00
100 mg: CNY ¥2091.00 / USD $209.10 / EUR €250.92 / JPY ¥37638.00
1 g: CNY ¥7408.00 / USD $740.80 / EUR €888.96 / JPY ¥133344.00
Note: The specific price is subject to the transaction price in the offline contract. This document is provided for technical reference only and does not constitute any form of sales advertisement or invitation to offer. For product details and purchase inquiries, please contact local sales representatives.
